Drs. Peter Block and Philippe G. Steg discuss cardiovascular outcomes with PCSK9-inhibitor, alirocumab, after acute coronary syndrome.

Clinical Topics: Acute Coronary Syndromes, Cardiovascular Care Team, Dyslipidemia, Stable Ischemic Heart Disease, Lipid Metabolism, Nonstatins, Novel Agents, Statins, Chronic Angina

Keywords: ACC18, ACC Annual Scientific Session, Angina, Stable, Cholesterol, LDL, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Acute Coronary Syndrome, Maximum Tolerated Dose, Brain Ischemia, Stroke, Antibodies, Monoclonal, Angina, Unstable, Apolipoproteins B, Myocardial Infarction, Coronary Disease, Treatment Outcome, Hospitalization, Subtilisins

< Back to Listings